CLAG-M (Cladribine + Cytarabine + Filgrastim + Mitoxantrone . . . CLAG-M is typically given to patients with relapsed or refractory AML after one or more prior treatments The goal of CLAG-M is to eliminate leukemia cells from the body and to decrease symptoms from AML, such as bleeding, bruising, and recurrent infections
CLAG-Based Induction Therapy in Previously Untreated High . . . CLAG-based therapy is a well-tolerated, efficacious induction strategy in previously-untreated patients with high risk AML CLAG-based regimens should be studied in a broader group of newly diagnosed AML patients
Venetoclax plus CLAG-M for the Treatment of Relapsed or . . . This phase II trial compares the effect of venetoclax plus cladribine, cytarabine, filgrastim and mitoxantrone (CLAG-M) to CLAG-M alone in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed), or that has not responded to previous treatment (refractory)
CLAG - Chemocare CYTARABINE (sye TARE a been) treats leukemia It works by slowing down the growth of cancer cells
CLAG±M (cladribine, cytarabine, granulocyte colony . . . Conclusions: CLAG±M resulted in high clinical responses and prolonged overall survival in pts with secondary and r r AML with poor risk features, specifically older age (³60 years old) and multiple prior lines of therapy including previous HMA
Venetoclax added to CLAG regimen might improve the outcome of . . . We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida Mito) regimen as a salvage treatment of relapsed refractory acute
CLAG-Based Chemotherapy in Previously Untreated AML Patients . . . This study was approved by the IRB of New York Medical College Results: We analyzed all 87 newly-diagnosed AML patients that were treated with CLAG-based induction therapy (CLAG alone: 10%, CLAG-IDA: 87%, CLAG-M: 3%) 4 patients with a FLT-3 mutation received a FLT-3 inhibitor concurrently
Medicine - LWW The CLAG-related regimen is an effective and safe therapy for R R AML patients, CLAG seems to have more superiority than CLAG combined therapy, though further studies including cladribine combination treatment protocols, are still needed to confirm our results further
CLAG-M with dose-escalated mitoxantrone for adults with acute . . . Our study adds to the evidence supporting the use of CLAG-M for intensive AML re-induction therapy, perhaps particularly with higher mitoxantrone doses Perhaps more importantly, our study points to a role of this regimen in the upfront setting where it is currently not commonly used